Related Experiment Videos
The pharmacokinetics of slow-release procainamide
European Journal of Clinical Pharmacology
|December 1, 1978
Summary
Oral procainamide (Durules) showed high absorption (97.6%) with a longer elimination half-life (6.0 h) compared to intravenous administration (3.4 h). Acetylator status influenced intravenous elimination but not oral absorption or elimination.
Area of Science:
- Pharmacokinetics
- Clinical Pharmacology
Background:
- Procainamide is an antiarrhythmic drug.
- Understanding its absorption and elimination is crucial for therapeutic efficacy.
Purpose of the Study:
- To evaluate the pharmacokinetics of slow-release oral procainamide (Durules) in patients with normal renal function.
- To compare oral and intravenous administration routes.
Main Methods:
- 20 patients with normal renal function received intravenous procainamide followed by oral slow-release formulation (Durules).
- Absorption, elimination half-life, and steady-state concentrations were measured.
- The influence of acetylator status was assessed.
Main Results:
- Oral procainamide demonstrated high absorption (97.6%) with an absorption half-life of 1.54 h.
- The elimination half-life was significantly longer for oral (6.0 h) versus intravenous (3.4 h) administration.
- Intravenous elimination half-life was influenced by acetylator status, but oral elimination was not.
- Total body clearance and steady-state concentrations were generally independent of acetylator status, though some slow acetylators had high concentrations.
Conclusions:
- Slow-release oral procainamide (Durules) is well-absorbed and has a prolonged elimination half-life compared to IV administration.
- Acetylator status significantly impacts intravenous procainamide elimination but not oral elimination.
- Dosing adjustments may be necessary for slow acetylators, particularly at higher oral doses.